Join to access to all OVN content. Join for Free
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
City of Hope Academic Research CAR T-cell Solid Tumor Glioblastoma brain tumor

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.


Share This Article



Summary

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Christine Brown, Ph.D., Deputy Director of the T Cell Research Laboratory at City of Hope, joins Monty Pal, M.D., F.A.S.C.O., to discuss how years of research in glioblastoma, one of the most aggressive and difficult brain cancers, are helping scientists rethink how CAR T cell therapy could effectively treat solid tumors.

In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Christine Brown, Ph.D., Deputy Director of the T‑Cell Research Laboratory at City of Hope, joins Monty Pal, M.D., F.A.S.C.O., to discuss how years of research in glioblastoma, one of the most aggressive and difficult brain cancers, are helping scientists rethink how CAR T‑cell therapy could effectively treat solid tumors.  

Dr. Brown shares lessons learned from treating patients with few options, including how tumors change over time and how the brain’s environment can limit immune‑based treatments. 

The conversation explores Brown’s early leadership in delivering CAR T cells directly into the brain, rather than through the bloodstream. The episode delves into her key clinical experiences that revealed both the potential of CAR T‑cell therapy and the challenges of making clinical responses last. 

Dr. Brown explains new up and coming approaches designed to improve durability and effectiveness, how these advances could extend beyond cancer to autoimmune diseases. She returns to a simple point: studying how real patients respond—what works, what doesn’t, and why—will shape every next step in her research. 

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review
OVN Avatar Ruben Van Paemel, Roos Vlug, Katleen De Preter, Nadine Van Roy, Frank Speleman, Leen Willems, Tim Lammens, Geneviève Laureys, Gudrun Schleiermacher, Godelieve A. M. Tytgat, Kathy Astrahantseff, Hedwig Deubzer, Bram De Wilde

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review

Podcast
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Partner Avatar Monty Pal

What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.

Podcast
The Long Game of Cancer Genomics: John Carpten, Ph.D., on Building Precision Oncology that Reaches Patients
Partner Avatar Monty Pal

The Long Game of Cancer Genomics: John Carpten, Ph.D., on Building Precision Oncology that Reaches Patients

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Explore OVN